Tech Company Financing Transactions
Arrien Pharmaceuticals Funding Round
On 9/12/2011, Arrien Pharmaceuticals received $2 million in Series A funding from private investors.
Transaction Overview
Company Name
Announced On
9/12/2011
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series A
Investors
Proceeds Purpose
Arrien has identified an active First-in-Class ARN-1032 and ARN-3016 which are potent inhibitors of protein kinases and demonstrated potent anticancer activities in a variety of cancer cell lines. Currently Arrien is conducting lead optimization process and early PK studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9980 South 300 West 200
Salt Lake City, UT 84070
USA
Salt Lake City, UT 84070
USA
Phone
Website
Email Address
Overview
Arrien Pharmaceuticals is a small molecule-targeted therapeutics drug discovery and development company targeting cell signaling pathways.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Rajendra Appalaneni
Chief Scientific Officer
Hariprasad Vankayalapati
VP - Bus. Development
David Zarling
Browse more venture capital transactions:
Prev: 9/12/2011: Noveda Technologies venture capital transaction
Next: 9/12/2011: Qstream venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs